(Reuters) -Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to ...

(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat ...

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...

Revenue missed analyst estimates by 99%. Earnings per share (EPS) also missed analyst estimates by 3.1%. Looking ahead, ...

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy ...

Eyenovia said Friday it plans to cut half of its workforce after results from a Phase 3 study missed their primary endpoint. The pharmaceutical company had 57 full-time employees as of March 15. There ...

Recent health news highlights include CareMax filing for Chapter 11 restructuring due to significant debts, a severe dengue ...

Eyenovia (EYEN) announced that a review of the CHAPERONE data by an independent Data Review Committee found that the trial is not meeting its ...

Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options ...

The latest health brief highlights a severe dengue outbreak in Bangladesh, California's first Clade I Mpox case, and Oregon's ...

Greetings and welcome to Eyenovia's Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.